People: Metabolix Inc (MBLX.O)

MBLX.O on Consolidated Issue listed on NASDAQ Global Market

8.90USD
10:19am EST
Price Change (% chg)

$-0.30 (-3.26%)
Prev Close
$9.20
Open
$9.13
Day's High
$9.13
Day's Low
$8.90
Volume
15,232
Avg. Vol
124,621
52-wk High
$13.45
52-wk Low
$4.62

view people for:

Summary

Name Age Since Current Position
Kouba, Jay 56 2008 Chairman of the Board
Muller, Edward 72 2007 Chairman Emeritus
Eno, Richard 48 2008 President, Chief Executive Officer, Director
Hill, Joseph 47 2008 Chief Financial Officer, Treasurer
Van Walsem, Johan 43 2009 Vice President - Commercial Development
Peoples, Oliver 50 2000 Vice President - Research & Development, Chief Scientific Officer, Director
Cecil, Sarah 57 2006 General Counsel
Engle, Robert 46 2009 General Manager - Telles
Giles, Edward 72 1993 Director
Sinskey, Anthony 69 1992 Director
Strobeck, Matthew 35 2006 Director
Van Nostrand, Robert 52 2006 Director
Kellogg, Peter 53 2007 Director
» Insider Trading

Biographies

Name Description
Kouba, Jay Jay Kouba, Ph.D., has served as a Director of Metabolix Inc. since June 2006 and as Chairman of the Board since April 2007. From May 2007 until March 2008, Dr. Kouba was the President and Chief Executive Officer of the Company. Since May 2008, Dr. Kouba has been the President and Chief Executive Officer of Tetra Vitae Bioscience. From January 2006 until May 2007, Dr. Kouba served as the President of Oniro Consulting, a strategic management consulting firm. From January 1999 to December 2005, Dr. Kouba held several positions with BP's Petrochemicals Segment. From August 2004 to December 2005, Dr. Kouba served as Senior Vice President, Strategy, Marketing and Technology for Innovene, BP's olefins and polymers subsidiary, earlier in 2004, as Vice President, Sales, Marketing and Logistics, and between 1999 and 2003, as Vice President, Technology. Dr. Kouba is also a Director of Telles, LLC, the Company's joint venture with Archer Daniels Midland Company. Dr. Kouba received a B.S. in Chemistry from Stanford University, a Ph.D. in Chemistry from Harvard University and a M.B.A. from the University of Chicago.
Muller, Edward Edward M. Muller has served as a Director of Metabolix Inc. since November 1993 and was the Chairman of the Board of Directors of the Company from November 1993 until April 2007. He was previously President and Chief Executive Officer of the Company from October 1993 to January 2000. Mr. Muller held a number of positions, including Chief Executive Officer, while at Halcon-SD Group between 1961 and 1985. That company developed a number of key processes for the production of raw materials for the polyester, nylon, polystyrene, and polyurethane industries. Mr. Muller serves on the Board of Directors of Tepha, Inc. (see "Certain Relationships and Related Person Transactions"). Mr. Muller received a B.Ch.E. from The Cooper Union and an M.B.A. in Finance and Economics from New York University.
Eno, Richard Richard P. Eno has served as President and Chief Executive Officer and as a Director since joining Metabolix Inc. in March 2008. From 2002 until he joined Metabolix, Mr. Eno was the Vice President, and Leader of Global Oil and Gas Practice, of CRA International, a consulting firm. From 1990 to 2002, Mr. Eno was with Arthur D. Little, a consulting firm, in a variety of positions of increasing responsibility, including Vice President, and from 1982 to 1990 he held several positions with Chevron Corporation. Mr. Eno is also a Director of Telles, LLC, the Company's joint venture with Archer Daniels Midland Company. Mr. Eno received a B.S. in Chemical Engineering from Cornell University and an M.B.A. from the University of Houston and is a Chartered Financial Analyst.
Hill, Joseph Joseph D. Hill has served as Chief Financial Officer of Metabolix Inc. since April 8, 2008. From 2004 until joining the Company, Mr. Hill served as Senior Vice President, Chief Financial Officer at Amicas, Inc., an independent provider of radiology image and information management solutions. Prior to that, from 2003 to 2004 he was Vice President and Chief Financial Officer at Dirig Software, a privately held provider of application performance management software systems. From 2000 to 2003, Mr. Hill served as Vice President, Chief Financial Officer and Director of Maconomy, a publicly traded provider of web-based business management solutions. Mr. Hill has a B.S. from Bryant College and an M.S.F. from Bentley College.
Van Walsem, Johan Mr. Johan Van Walsem has been appointed as Vice President - Commercial Development of Metabolix, Inc effective August 3, 2009. He has served as the Company's Vice President of Manufacturing, Development and Operations since October 2003, and was previously its Director of Manufacturing and Development from September 2001 to October 2003. Prior to joining Metabolix, from December 2000 to September 2001, Mr. Van Walsem was senior biochemical engineer with Montec Research, a division of Resodyn Corporation, where he was responsible for all fermentation technology development. Prior to that, Mr. Van Walsem worked with AECI Bioproducts in South Africa in technology management and new product development, commercializing the first large scale biotechnology-based amino acid production in Africa. Mr. Van Walsem received a master’s degree in Chemical Engineering from the University of Pretoria (South Africa) and an Master of Business Administration from the University of South Africa.
Peoples, Oliver Oliver P. Peoples, Ph.D., a co-founder of Metabolix Inc., has served as Chief Scientific Officer and Vice President of Research and Development since January 2000 and was previously Director of Research and Vice President. Dr. Peoples has served as a Director since June 1992. Before founding Metabolix, Dr. Peoples was a research scientist with the Department of Biology at the MIT where he emerged as a pioneer of the new field of metabolic pathway engineering and its applications in industrial biotechnology. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples has published numerous peer-reviewed academic papers and is an inventor of over 90 patents and patent applications worldwide. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
Cecil, Sarah Sarah P. Cecil has served as legal counsel to Metabolix Inc. since July 2005 and as General Counsel since the Company's initial public offering in November 2006. Previously, she was corporate counsel at Vertex Pharmaceuticals from 1992 until 2001, and at Biogen, Inc. from 1985 until 1991. Ms. Cecil's legal practice has also included clients in the food ingredients, computer services and clinical research industries, as well as several biotechnology companies. Ms. Cecil received an A.B. from Brown University, and she was a C.P.A. with Price Waterhouse (currently PricewaterhouseCoopers) before obtaining a J.D. from Harvard Law School.
Engle, Robert Robert E. Engle joined Metabolix Inc. in January 2009 as General Manager, Telles after ten years with Ticona, the engineering polymers business of Celanese Corporation, where he served from 2005 to 2008 as Ticona's Vice President of Affiliate Management, responsible for oversight of Ticona's global joint venture affiliate relationships in the high performance plastics industry and from 1999 to 2005 as Business Director, Ticona Engineering Plastics. In addition, he has served on the Boards of Directors of several international joint ventures, including Polyplastics, Korea Engineering Plastics and Fortron Industries. Prior to his experience at Ticona, Mr. Engle worked in corporate planning at Hoechst A.G. and in a chemicals and plastics consulting role at Arthur D. Little. Mr. Engle holds a bachelor's degree in chemical engineering from the University of Colorado and received a master's degree in Arabic focused on international business administration from Georgetown University.
Giles, Edward Edward M. Giles has served as a Director of Metabolix, Inc. since November 1993. He is managing member of GME Capital LLC since 2005. Mr. Giles was Chairman of The Vertical Group, Inc., an investment fund administration company from 1989 through 2006, and now serves as its Chairman Emeritus. Mr. Giles was previously President of F. Eberstadt & Co., Inc., a securities firm. Mr. Giles also serves on the Board of Directors of Tepha, Inc. (see "Certain Relationships and Related Person Transactions"). Mr. Giles received a B.Ch.E. from Princeton University, and an S.M. in Industrial Management from Massachusetts Institute of Technology (MIT).
Sinskey, Anthony Anthony J. Sinskey, Sc.D., a co-founder of Metabolix Inc., has served as a Director since June 1992. From 1968 to present, Dr. Sinskey has been on the faculty of MIT. Currently at MIT, he serves as Professor of Microbiology in the Department of Biology and Professor of Health Sciences and Technology in the Harvard-MIT Health Sciences and Technology Program, as well as Co-Director of the Center for Biomedical Innovation. Dr. Sinskey serves on the Board of Directors of Tepha, Inc. (see "Certain Relationships and Related Person Transactions"). Dr. Sinskey received a B.S. from the University of Illinois and a Sc.D. from MIT.
Strobeck, Matthew Matthew Strobeck, Ph.D., has served as a Director of Metabolix Inc. since September 2006. From May 2003 to the present, Dr. Strobeck has served as a senior investment analyst at Westfield Capital Management, specializing in healthcare and life sciences. Dr. Strobeck previously served as a consultant to the senior economic advisor to the commissioner of the Food and Drug Administration from August 2003 to May 2004. Dr. Strobeck was a fellow in the Department of Biology at MIT from December 2001 to June 2002. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, a S.M. from Harvard University and a S.M. from the MIT Sloan School of Management.
Van Nostrand, Robert Robert L. Van Nostrand has served as a Director of Metabolix Inc. since October 2006. From July 2007 until the company was sold in September 2008, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc., a private company focused on the development and commercialization of skin care products and a drug for the prevention of skin cancer. Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. from 1986 to 2007, serving as Senior Vice President and Chief Compliance Officer from May 2005 until July 2007, and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. (currently Deloitte and Touche). Mr. Van Nostrand serves on the Board of Directors and is Chairman of the Audit Committee of both Apex Bioventures, Inc. and Achillion Pharmaceuticals, Inc. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, and completed advanced management studies at the Wharton School, and he is a Certified Public Accountant.
Kellogg, Peter Peter N. Kellogg has served as a Director of Metabolix Inc. since March 30, 2007. Since August 2007, he has been Executive Vice President and Chief Financial Officer of Merck & Co., Inc. He joined Merck in 2007 after serving as Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc. From 2000 to 2003, Mr. Kellogg held the same position at Biogen, Inc., which merged with IDEC Pharmaceuticals in 2003. Before that, he served as Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc. from March to July 2000 and as Senior Vice President and Chief Financial Officer, Frito-Lay International, from March 1998 to March 2000. From 1987 to 1998, he served in a variety of senior financial, international and general management positions at PepsiCo and the Pepsi-Cola International, Pepsi-Cola North America, and Frito-Lay International divisions. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Arthur Andersen & Co. and Booz Allen & Hamilton. Mr. Kellogg holds an M.B.A. in Management from the University of Pennsylvania and a B.S. in Engineering from Princeton University.

Basic Compensation

Name Fiscal Year Total
Kouba, Jay 1,042,730
Muller, Edward --
Eno, Richard --
Hill, Joseph --
Van Walsem, Johan 470,882
Peoples, Oliver 463,182
Cecil, Sarah --
Engle, Robert --
Giles, Edward --
Sinskey, Anthony --
Strobeck, Matthew --
Van Nostrand, Robert --
Kellogg, Peter --
As Of 30 Dec 2007

Options Compensation

Name Options Value
Kouba, Jay 0 0
Muller, Edward 0 0
Eno, Richard 0 0
Hill, Joseph 0 0
Van Walsem, Johan 317,000 791,369
Peoples, Oliver 421,057 1,162,770
Cecil, Sarah 0 0
Engle, Robert 0 0
Giles, Edward 0 0
Sinskey, Anthony 0 0
Strobeck, Matthew 0 0
Van Nostrand, Robert 0 0
Kellogg, Peter 0 0

Insider Trading

Name Shares Traded Price
VAN WALSEM JOHAN 6,000 $13.25
CECIL SARAH P 8,173 $1.65
CECIL SARAH P 8,173 $12.00
SINSKEY ANTHONY J 4,400 $12.00
SINSKEY ANTHONY J 10,600 $12.00
GILES EDWARD M 43,414 $11.29
STROBECK MATTHEW 40,000 $7.95
MULLER EDWARD M 15,000 $10.62
GILES EDWARD M 20,146 $0.00
GILES EDWARD M 61,886 $0.00
GILES EDWARD M 61,886 $0.00
GILES EDWARD M 20,146 $0.00
MULLER EDWARD M 600 $10.67
MULLER EDWARD M 1,800 $11.40
MULLER EDWARD M 200 $10.59
MULLER EDWARD M 200 $10.64
MULLER EDWARD M 200 $11.16
MULLER EDWARD M 1,900 $10.55
MULLER EDWARD M 200 $10.61
MULLER EDWARD M 300 $10.66
MULLER EDWARD M 2,500 $11.25
MULLER EDWARD M 700 $10.57
MULLER EDWARD M 600 $10.63
MULLER EDWARD M 1,600 $11.15
MULLER EDWARD M 700 $11.65
» Full list on Insider Trading
view people for: